Immunic Inc (IMUX)

12:32 PM

12 Best Penny Stocks Under $1 to Buy Now - Insider Monkey

12:32 PM

07:40 AM

Immunic Inc. Stock Analysis and ForecastHigh-yield investments - jammulinksnews.com

07:40 AM

04:36 AM

Is Immunic Inc. a good long term investmentConsistent double returns - jammulinksnews.com

04:36 AM

Jul 22, 2025

What analysts say about Immunic Inc. stockFastest return on investment - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

World Brain Day: Immunic targets MS with new therapy - Proactive financial news

Jul 22, 2025

Jul 19, 2025

What drives Immunic Inc. stock priceOutstanding risk-reward balance - jammulinksnews.com

Jul 19, 2025

Jul 17, 2025

IMUX’s Stock Market Puzzle: Piecing Together 2025’s Performance - investchronicle.com

Jul 17, 2025

Jul 15, 2025

What makes Immunic Inc. stock price move sharplyValue Pick Scanner - Newser

Jul 15, 2025

Jul 15, 2025

How Immunic Inc. stock performs during market volatilityFree Top Growth Stock Recommendations - Newser

Jul 15, 2025

Jul 15, 2025

Why Immunic Inc. stock attracts strong analyst attentionFree Capital Allocation Plans - Newser

Jul 15, 2025

Jul 11, 2025

Immunic board authorizes up to 35 million stock appreciation rights for employees By Investing.com - Investing.com South Africa

Jul 11, 2025

Jul 11, 2025

Immunic board authorizes up to 35 million stock appreciation rights for employees - Investing.com Australia

Jul 11, 2025

Jul 08, 2025

KULR Technology Group Announces $20 Million Credit Facility with Coinbase - Stocktwits

Jul 08, 2025

Jul 07, 2025

Immunic, Inc. Announces Proposed Public Offering - NewsBreak: Local News & Alerts

Jul 07, 2025

Jul 07, 2025

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - NewsBreak: Local News & Alerts

Jul 07, 2025

Jul 07, 2025

Immunic to Participate in Scientific and Industry Conferences in May - NewsBreak: Local News & Alerts

Jul 07, 2025

Jul 07, 2025

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial By Stocktwits - Investing.com India

Jul 07, 2025

Jul 07, 2025

Immunic, Inc. Announces Proposed Public Offering By Stocktwits - Investing.com India

Jul 07, 2025

Jul 07, 2025

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering By Stocktwits - Investing.com India

Jul 07, 2025

Jul 07, 2025

Immunic to Participate in Scientific and Industry Conferences in May By Stocktwits - Investing.com India

Jul 07, 2025

Jul 06, 2025

Immunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of “Buy” by Brokerages - Defense World

Jul 06, 2025

Jul 03, 2025

Immunic to Participate in Investor, Scientific and Industry Conferences in June - MSN

Jul 03, 2025

Jul 02, 2025

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering - NewsBreak: Local News & Alerts

Jul 02, 2025

Jul 02, 2025

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS By Stocktwits - Investing.com India

Jul 02, 2025

Jul 02, 2025

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis By Stocktwits - Investing.com India

Jul 02, 2025

Jul 02, 2025

Immunic to Participate in Investor, Scientific and Industry Conferences in June By Stocktwits - Investing.com India

Jul 02, 2025

Jul 02, 2025

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering By Stocktwits - Investing.com India

Jul 02, 2025

Jun 28, 2025

Immunic CEO discusses Phase 2 multiple sclerosis study successICYMI - Proactive Investors

Jun 28, 2025

Jun 27, 2025

Immunic reveals MS drug trial success - Proactive Investors

Jun 27, 2025

Jun 27, 2025

Immunic reveals MS drug trial success | NASDAQ:IMUX - Proactive Investors

Jun 27, 2025

Jun 24, 2025

Immunic reports low disability worsening rates in MS drug trial By Investing.com - Investing.com Nigeria

Jun 24, 2025

Jun 24, 2025

Immunic reveals long-term data supporting potential of MS drug vidofludimus calcium - Proactive financial news

Jun 24, 2025

Jun 24, 2025

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis - Stocktwits

Jun 24, 2025

Jun 19, 2025

Immunic highlights MS treatment progression at BIO International Convention in Boston - Proactive Investors

Jun 19, 2025

Jun 17, 2025

Financial Metrics Check: Immunic Inc (IMUX)’s Ratios for Trailing Twelve Months - DWinneX

Jun 17, 2025

Jun 12, 2025

Phase 3 trials of vidofludimus calcium in relapsing MS enrolled - Multiple Sclerosis News Today

Jun 12, 2025

Jun 11, 2025

Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of “Buy” by Brokerages - Defense World

Jun 11, 2025